PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, includin… Read more
PDS Biotechnology Corp (PDSB) - Total Assets
Latest total assets as of September 2025: $34.71 Million USD
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) holds total assets worth $34.71 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PDS Biotechnology Corp - Total Assets Trend (2012–2024)
This chart illustrates how PDS Biotechnology Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PDS Biotechnology Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
PDS Biotechnology Corp's total assets of $34.71 Million consist of 99.3% current assets and 0.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how PDS Biotechnology Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PDS Biotechnology Corp's current assets represent 99.3% of total assets in 2024, an increase from 90.0% in 2012.
- Cash Position: Cash and equivalents constituted 91.9% of total assets in 2024, up from 86.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
PDS Biotechnology Corp Competitors by Total Assets
Key competitors of PDS Biotechnology Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
PDS Biotechnology Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PDS Biotechnology Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PDS Biotechnology Corp is currently not profitable relative to its asset base.
PDS Biotechnology Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 2.84 | 9.28 |
| Quick Ratio | 2.09 | 2.84 | 9.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.56 Million | $ 33.79 Million | $ 27.07 Million |
PDS Biotechnology Corp - Advanced Valuation Insights
This section examines the relationship between PDS Biotechnology Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.14 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | -23.6% |
| Total Assets | $45.36 Million |
| Market Capitalization | $32.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values PDS Biotechnology Corp's assets below their book value (0.73 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: PDS Biotechnology Corp's assets decreased by 23.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PDS Biotechnology Corp (2012–2024)
The table below shows the annual total assets of PDS Biotechnology Corp from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $45.36 Million | -23.63% |
| 2023-12-31 | $59.39 Million | -22.88% |
| 2022-12-31 | $77.01 Million | +14.60% |
| 2021-12-31 | $67.20 Million | +117.54% |
| 2020-12-31 | $30.89 Million | +113.17% |
| 2019-12-31 | $14.49 Million | -59.99% |
| 2018-12-31 | $36.22 Million | -60.89% |
| 2017-12-31 | $92.62 Million | -16.49% |
| 2016-12-31 | $110.91 Million | -17.29% |
| 2015-12-31 | $134.09 Million | +686.62% |
| 2014-12-31 | $17.05 Million | +95.18% |
| 2013-12-31 | $8.73 Million | +5233.42% |
| 2012-12-31 | $163.76K | -- |